From Financial Modeling Prep: 2024-11-04 16:00:01

Exact Sciences Corporation (NASDAQ:EXAS) is gaining attention for its innovative cancer screening and diagnostic tests, like the Cologuard test for colorectal cancer. Analysts have raised the consensus price target for EXAS to $95, indicating a potential 34.3% increase in stock value. Jefferies analyst Brandon Couillard sets an ambitious price target of $140 based on the company’s potential to surpass earnings estimates. Exact Sciences’ focus on enhancing diagnostic tests and partnerships is expected to boost Precision Oncology revenues, contributing to a positive third-quarter earnings performance. The company’s recent upgrade to a Zacks Rank #1 (Strong Buy) reflects growing optimism about its future performance.



Read more at Financial Modeling Prep:: Exact Sciences Corporation (NASDAQ:EXAS) Shows Pro…